Marquette University

e-Publications@Marquette
Biomedical Engineering Faculty Research and
Publications

Biomedical Engineering, Department of

11-2019

Pharmacokinetics of 99mTc-HMPAO in Isolated Perfused Rat
Lungs
Anne V. Clough
Marquette University, anne.clough@marquette.edu

Katherine Barry
Marquette University

Benjamin Michael Rizzo
Marquette University, benjamin.rizzo@marquette.edu

Elizabeth R. Jacobs
Medical College of Wisconsin

Said H. Audi
Marquette University, said.audi@marquette.edu

Follow this and additional works at: https://epublications.marquette.edu/bioengin_fac
Part of the Biomedical Engineering and Bioengineering Commons

Recommended Citation
Clough, Anne V.; Barry, Katherine; Rizzo, Benjamin Michael; Jacobs, Elizabeth R.; and Audi, Said H.,
"Pharmacokinetics of 99mTc-HMPAO in Isolated Perfused Rat Lungs" (2019). Biomedical Engineering
Faculty Research and Publications. 611.
https://epublications.marquette.edu/bioengin_fac/611

Marquette University

e-Publications@Marquette
Biomedical Engineering Faculty Research and Publications/College of
Engineering
This paper is NOT THE PUBLISHED VERSION; but the author’s final, peer-reviewed manuscript. The
published version may be accessed by following the link in th citation below.

Journal of Applied Physiology, Vol. 127, No. 5 (November 2019): 1317-1327. DOI. This article is ©
American Physiological Society and permission has been granted for this version to appear in ePublications@Marquette. American Physiological Society does not grant permission for this article to
be further copied/distributed or hosted elsewhere without the express permission from American
Physiological Society.

Pharmacokinetics of 99mTc-HMPAO in Isolated
Perfused Rat Lungs
Anne V. Clough
Department of Mathematics, Statistics, and Computer Science, Marquette University, Milwaukee,
Wisconsin
Milwaukee Veterans Affairs Medical Center, Milwaukee, Wisconsin

Katherine Barry
Department of Biomedical Engineering, Marquette University, Milwaukee, Wisconsin

Benjamin M. Rizzo
Department of Mathematics, Statistics, and Computer Science, Marquette University, Milwaukee,
Wisconsin

Elizabeth R. Jacobs
Milwaukee Veterans Affairs Medical Center, Milwaukee, Wisconsin
Department of Medicine, Medical College of Wisconsin, Milwaukee, Wisconsin

Said H. Audi
Milwaukee Veterans Affairs Medical Center, Milwaukee, Wisconsin

Department of Biomedical Engineering, Marquette University, Milwaukee, Wisconsin

Abstract
Lung uptake of technetium-labeled hexamethylpropyleneamine oxime (HMPAO) increases in rat models of
human acute lung injury, consistent with increases in lung tissue glutathione (GSH). Since 99mTc-HMPAO uptake
is the net result of multiple cellular and vascular processes, the objective was to develop an approach to
investigate the pharmacokinetics of 99mTc-HMPAO uptake in isolated perfused rat lungs. Lungs of anesthetized
rats were excised and connected to a ventilation-perfusion system. 99mTc-HMPAO (56 MBq) was injected into the
pulmonary arterial cannula, a time sequence of images was acquired, and lung time-activity curves were
constructed. Imaging was repeated with a range of pump flows and perfusate albumin concentrations and
before and after depletion of GSH with diethyl maleate (DEM). A pharmacokinetic model of 99mTc-HMPAO
pulmonary disposition was developed and used for quantitative interpretation of the time-activity curves.
Experimental results reveal that 99mTc-HMPAO lung uptake, defined as the steady-state value of the 99mTcHMPAO lung time-activity curve, was inversely related to pump flow. Also, 99mTc-HMPAO lung uptake decreased
by ~65% after addition of DEM to the perfusate. Increased perfusate albumin concentration also resulted in
decreased 99mTc-HMPAO lung uptake. Model simulations under in vivo flow conditions indicate that lung tissue
GSH is the dominant factor in 99mTc-HMPAO retention in lung tissue. The approach allows for evaluation of the
dominant factors that determine imaging biomarker uptake, separation of the contributions of pulmonary
versus systemic processes, and application of this knowledge to in vivo studies.
NEW & NOTEWORTHY We developed an approach for studying the pharmacokinetics of technetium-labeled
hexamethylpropyleneamine oxime (99mTc-HMPAO) in isolated perfused lungs. A distributed-in-space-and-time
computational model was fit to data and used to investigate questions that cannot readily be addressed in vivo.
Experimental and modeling results indicate that tissue GSH is the dominant factor in 99mTc-HMPAO retention in
lung tissue. This modeling approach can be readily extended to investigate the lung pharmacokinetics of other
biomarkers and models of lung injury and treatment thereof.

INTRODUCTION
Technetium-labeled hexamethylpropyleneamine oxime (99mTc-HMPAO) is a radiolabeled compound used in
clinical single-photon emission tomography (SPECT) brain perfusion imaging because of its prolonged flowdependent retention (17). In addition, increased 99mTc-HMPAO lung uptake has been reported in patients with
lung injury resulting from chemotherapy and radiation injury in the absence of perfusion impairment or
roentgenographic abnormalities (25) and in patients with diffuse infiltrative lung disease (13). Also, we and
others have reported the potential utility of 99mTc-HMPAO imaging for detecting and monitoring lung injury in
preclinical models involving prolonged exposure to high concentrations of oxygen (hyperoxia) (4, 5, 10), the
sepsis mimic lipopolysaccharide (6), and chemotoxic agents (12). These studies revealed increased lung uptake
in subjects with subclinical lung injury, suggesting that 99mTc-HMPAO imaging may be a means for quantitatively
detecting lung injury before detection with conventional clinical tools and for assessing the efficacy of novel
therapies (5).
HMPAO exists in two forms: the oxidized cell-permeant form and the reduced cell-impermeant form (20). The
oxidized form is highly lipophilic, with an octanol-water partition coefficient of ~83, compared with 0.006 for the
reduced form (2). Thus 99mTc-HMPAO uptake is dependent on the rate of diffusion of the oxidized form across
the cell membrane, where once across the cell membrane it is converted to its reduced cell-impermeant form
and retained within the tissue or diffuses back to the blood. The intracellular conversion and retention of
HMPAO are dependent in part on the oxidoreductive state of the tissue including the intracellular content of the
antioxidant glutathione (GSH) (4, 20).

Lung tissue GSH content increases in response to oxidative stress, which plays a key role in the pathogenesis of
lung diseases, including acute lung injury (16, 21). We and others have demonstrated that the lung uptake of
HMPAO is dependent on lung tissue GSH content (4–6) and hence can serve as a biomarker of lung tissue GSH
content. However, lung uptake of 99mTc-HMPAO is the net result of multiple cellular and vascular processes,
including cardiac output, plasma and tissue GSH content, plasma protein binding, uptake by other organs,
capillary endothelial permeability, and mitochondrial and/or cytosolic redox status (1, 17, 19, 20). Each of these
cellular and vascular processes, most of which cannot be assessed in vivo, can vary with acute illness. Thus
clinical use of 99mTc-HMPAO for assessing lung pathology necessitates knowledge of the sensitivity and
specificity of uptake to changes in the targeted lung cellular process (i.e., GSH content) induced by the disease
pathology versus alteration of some other process(es) (e.g., cardiac output, vascular permeability, input
function) (4, 17).
The objective of this study was to use 99mTc-HMPAO imaging of an isolated perfused lung (IPL) to readily and
knowingly manipulate the vascular and tissue processes hypothesized to determine 99mTc-HMPAO lung uptake.
The pharmacokinetics of 99mTc-HMPAO uptake in the lung were investigated via experimental studies, and a
physiologically based pharmacokinetic (PBPK) model (8, 9) descriptive of 99mTc-HMPAO disposition in the lung
was used to estimate parameters descriptive of the various processes.
There is ample evidence that the lung uptake of 99mTc-HMPAO is relatively fast on passage through the
pulmonary circulation (4, 6, 10). Thus the assumption of well-mixed compartments made by existing models
for 99mTc-HMPAO brain pharmacokinetics (1, 2, 17, 20) may not be appropriate in the lung, especially since lung
capillary perfusion is highly heterogeneous, with some pathways having short transit times and other having
long transit times (23). Furthermore, the injected bolus contains the oxidized form of 99mTc-HMPAO, which is
highly lipophilic (2). Thus we developed a distributed-in-space-and-time PBPK model for interpretation of the
measured lung time-activity curves (TACs).

MATERIALS AND METHODS
HMPAO (Ceretec) was purchased in kit form from GE Healthcare (Arlington Heights, IL). Diethyl maleate (DEM)
and other reagent-grade chemicals were purchased from Sigma-Aldrich (St. Louis, MO).

Experimental methods.
This protocol was approved by the Institutional Animal Care and Use Committee of the Department of Veterans
Affairs Medical Center (Milwaukee, WI). Adult male Sprague-Dawley rats [352 ± 7 (SE) g, n = 11] were
anesthetized (pentobarbital sodium, 40–50 mg/kg), the lungs were excised, and the pulmonary artery,
pulmonary vein, and trachea were cannulated and connected to a ventilation-perfusion system as previously
described (23). The lungs were oriented in the upright position. Krebs-Ringer bicarbonate perfusate with 3% or
5% bovine serum albumin (BSA) was maintained at 37°C (pH = 7.4) (21), and lungs were ventilated at 40
breaths/min (15% O2 , 6% CO2 , balance N2 ) with end-inspiratory and end-expiratory airway pressures of ~6 and
3 mmHg, respectively.
A modular gamma camera (4.5 in. × 4.5 in.) attached to a parallel-hole collimator of a micro-SPECT system was
oriented vertically (4, 10). The collimator was positioned ~4 cm from the lung to maximize detection efficiency.
HMPAO was conjugated with pertechnetate (TcO−
4 ) according to kit directions. Each experiment began with
imaging of a calibration phantom (1.7-mL Eppendorf cuvette) containing ~150 MBq of pertechnetate, positioned
next to the lung. A bolus of 99mTc-HMPAO (~56 MBq in 0.2 mL) was loaded into an injection loop with two
parallel tubing segments, positioned upstream from the arterial cannula. At end-expiration, the ventilator was
stopped and the solenoid valve in the injection loop was activated to divert the lung inflow to the 99mTc-HMPAO

segment, without changing pressure or flow. Dynamic planar images were acquired every second for 1–2 min
(depending on flow) as the 99mTc-HMPAO bolus perfused the lung in this single-pass system. Ventilation was
restored upon completion of the imaging sequence. To evaluate the effect of perfusate flow on 99mTc-HMPAO
uptake, repeated bolus injections and imaging were performed with flows of 5, 10, and 15 mL/min and 3% BSA
perfusate. To determine the effect of protein in the perfusate, bolus injections and imaging were performed
with perfusate containing either 3% or 5% BSA at a flow of 10 mL/min. To determine the impact of the GSH
concentration in the lung, DEM (6 mM) was added to the perfusate reservoir and circulated through the lung for
10 min before 99mTc-HMPAO bolus injection and imaging.

Image analysis.
For each bolus injection, the time sequence of planar images was analyzed to determine the lung TAC
describing 99mTc-HMPAO lung uptake as a function of time (10). The sum of the time sequence of images was
displayed, and a region of interest (ROI) corresponding to the lung was manually outlined with ImageJ. Since
knowledge of the input curve to the lung is required for PBPK modeling (24), an ROI was also drawn over the
inflow cannula. The resulting ROI masks were then superimposed on the sequence of 99mTc-HMPAO images and
used to calculate TAC curves representing mean counts per pixel within both the lung and input ROIs for each
time frame. The preinjection baseline was subtracted from the curve to account for residual 99mTc-HMPAO from
the previous injection, followed by normalization to the injected dose and to the calibration phantom to obtain
the TAC in units of mean counts per pixel per second per injected dose for each ROI. Lung uptake was
determined as the mean of the lung TAC over the last 5 s of data acquisition, i.e., at steady state.
The image of the calibration phantom was used to calculate the fraction of injected 99mTc-HMPAO retained in
the lung. An ROI was drawn over the image of the phantom, and total counts acquired over 5 s were determined
from the phantom ROI. The known activity within the phantom was divided by the ROI counts to determine an
image count-to-activity conversion factor. Total counts acquired from the lung image ROI over the last 5 s of
imaging were also determined and converted to lung activity with this conversion factor. The fraction of 99mTcHMPAO retained in the lung was then calculated as lung activity divided by the known activity injected into the
lung.

BSA concentration in perfusate.
The influence of perfusate BSA concentration on the fraction of oxidized 99mTc-HMPAO bound to BSA was
studied with a Centrifree Ultrafiltration Device with Ultracel PL membrane (30,000 NMWL) (Millipore Sigma, St.
Louis, MO) as previously described (11). Perfusate solutions with BSA concentrations of 1.5%, 3%, and 5% (pH
7.4) were prepared. For a given concentration, 0.4 mL of 99mTc-HMPAO (~220 MBq/mL) was added to 1.6 mL of
perfusate; 0.1 mL of the mixture was placed in a 1-mL Eppendorf tube (sample 1), and another 0.8 mL was
transferred to the upper portion of the device. The device was then centrifuged for 3 min (2,000 g, 37°C); 0.1 mL
of the filtrate was then added to a different Eppendorf tube (sample 2). Activity in samples 1 and 2 was then
counted to obtain measures of total (BSA-bound + free) and free 99mTc-HMPAO in the perfusate.

EXPERIMENTAL RESULTS
Representative image frames acquired during 99mTc-HMPAO passage through the isolated lung, with pump flow
(F) = 10 mL/min and 3% BSA perfusate, are shown in Fig. 1. The corresponding inlet and outlet TACs are shown
in Fig. 2. The lung TAC consists of a throughput portion that dominates the early part of the curve and a tissue
uptake and retention portion that dominates the later, steady-state portion of the curve. The steady-state
portion is consistent with the reduced form being tissue impermeant.

Fig. 1. Representative image frames acquired during 99mTc-HMPAO passage through an isolated perfused lung
showing arterial input and lung regions of interest. Color scale represents counts/s.

Fig. 2. Representative arterial input and lung time-activity curves (TACs) after bolus injection of 99mTc-HMPAO
with 3% bovine serum albumin perfusate at pump flow = 10 mL/min. Curves normalized to injected dose
(ID). Lefty-axis is for input; righty-axis is for lung.
At F = 10 mL/min with 3% BSA perfusate, 35.9 ± 4.7% (SE; n = 8 rats) of the injected dose was retained in the lung
tissue during a single pass through the pulmonary circulation, consistent with the relatively high lipophilicity of
the oxidized form of 99mTc-HMPAO.
To determine the effect of flow on lung uptake of 99mTc-HMPAO, experiments were repeated at F = 5, 10, and 15
mL/min with 3% BSA perfusate. Representative lung TACs shown in Fig. 3A show that lung uptake, as measured
by the steady-state value of the lung TAC, was inversely related to F. Increasing F from 5 to 10 mL/min resulted
in a 36% decrease (paired t test, P < 0.001) in steady-state lung uptake (4.30 ± 0.30 at 5 mL/min vs. 2.74 ± 0.27 at
10 mL/min, n = 8 rats), as shown in Fig. 4. Increasing F to 15 mL/min did not result in a statistically significant
decrease in uptake (2.33 ± 0.15, n = 5 rats).

Fig. 3. Representative 99mTc-HMPAO lung time-activity curves. A: pump flow (F) = 5, 10, and 15 mL/min [3%
bovine serum albumin (BSA)]. B: 3% and 5% BSA perfusate at F = 10 mL/min. C: pre- and post-diethyl maleate
(DEM) at F = 5 mL/min. D: pre- and post-DEM at F = 10 mL/min. Curves normalized to injected dose (ID).

Fig. 4.99mTc-HMPAO lung uptake obtained under different experimental conditions, with 3% bovine serum
albumin (BSA) unless indicated otherwise. Numbers of rats in groups are indicated in the bars. *P < 0.05 in all
cases. DEM, diethyl maleate.
The effect of perfusate BSA concentration on lung uptake of 99mTc-HMPAO was evaluated with F = 10 mL/min,
with resulting TACs shown in Fig. 3B. Increasing BSA concentration from 3% (2.74 ± 0.27, n = 8 rats) to 5%
(1.92 ± 0.19, n = 7 rats) resulted in a ~30% decrease (P = 0.034, unpaired t test) in lung uptake (Fig. 4). This is
consistent with a decrease in the fraction of injected lipophilic 99mTc-HMPAO available for uptake on passage
through the lung with increased BSA concentration.
Figure 5 shows the relationship between perfusate %BSA and the ratio of bound (Bo)-to-free (Fr) 99mTc-HMPAO
in perfusate. The binding reaction
𝑘1

Fr + BSA ⇄ Bo
𝑘−1

Fig. 5. Ratio of bovine serum albumin (BSA) bound to 99mTc-HMPAO to free BSA in perfusate as a function of BSA
concentration in perfusate. Means ± SD; n = 4 rats. r 2 = 0.84
under the rapid equilibrium assumption, yields [Fr][BSA]𝑘1 = [Bo]𝑘−1 and hence
[Bo]
[Fr]

1

= [BSA] (𝐾 ) (1)
Dv

where 𝐾Dv is the equilibrium dissociation constant in units of %BSA. Data in Fig. 5 support this linear
relationship, consistent with rapidly binding equilibrium between BSA and 99mTc-HMPAO. The slope of the
regression line through the data yielded an estimated value of 𝐾Dv = 1.46%BSA, which was used in the model
fitting and simulations below. This result suggests that when perfusate BSA concentration was 3%, ~68%
of 99mTc-HMPAO in perfusate was bound to BSA.
The effect of lung tissue GSH content was evaluated by adding DEM to the perfusate, with representative TACs
shown in Fig. 3, C and D. DEM decreased lung uptake by 62% (4.46 ± 0.42 pre-DEM vs. 1.66 ± 0.14 post-DEM, n =
4 rats; paired t test, P = 0.004) at a flow of 5 mL/min and by 67% (2.93 ± 0.49 pre-DEM vs. 0.98 ± 0.17 postDEM, n = 4 rats; paired t test, P = 0.009) at 10 mL/min (Fig. 4). These results are consistent with a dominant role
for lung tissue GSH content in uptake and retention of 99mTc-HMPAO on passage through the pulmonary
circulation.

PBPK MODEL OF 99mTc-HMPAO PULMONARY DISPOSITION
Model development.
A distributed-in-time-and-space model (8) was developed and used for quantitative interpretation of the
measured lung TACs. The model incorporates the dominant cellular and vascular processes hypothesized to
determine the pulmonary disposition of 99mTc-HMPAO. A system of partial differential equations (PDEs) was
constructed that relaxes the assumption of well-mixed compartments and accounts for perfusion heterogeneity
within the pulmonary capillary region. The whole organ model then consists of conducting arteries and veins,
and capillary elements, each composed of a vascular region and its surrounding extravascular (tissue) region as
depicted in Fig. 6. A detailed derivation of the lung model, including the model PDEs, is presented in

the Appendix. Briefly, the injected oxidized form of 99mTc-HMPAO (𝑂𝑣 ) enters the capillary region, where it can
participate in rapidly equilibrating interactions with BSA in the perfusate with dissociation rate constant 𝐾𝐷𝑣 ,
diffuse into the extravascular region (PS), or exit the lung. Within the extravascular region, the oxidized form
(𝑂𝑒 ) converts to the reduced form (𝑅𝑒 ) via either a GSH-dependent (𝑘𝐺𝑆𝐻 ) pathway or other reductant (RH, GSH
independent, 𝑘𝑅𝐻 ) pathway that is retained, participates in rapidly equilibrating interactions with protein
(dissociation rate constant 𝐾𝐷𝑒 ), or diffuses back into the vascular region of the capillaries. The oxidized form in
the vasculature exits the capillary region via the conducting veins.

Fig. 6. Model of dominant processes involved in 99mTc-HMPAO (O, oxidized; R, reduced) distribution in a single
capillary element consisting of vascular (v, blood) and surrounding extravascular (e, cell/tissue) regions. GSH,
glutathione; V, volume; z, distance from the capillary inlet; RH, GSH-independent reductant; 𝐶𝑖𝑛 , capillary input
function; 𝐶𝑜𝑢𝑡 , capillary outlet function; PS, permeability surface-area product; BSA, protein.
The resulting PDEs describing the spatial and temporal changes in the concentration of oxidized and
reduced 99mTc-HMPAO in the vascular and extravascular regions of a capillary element derived in
the Appendix are given by
𝜕𝑂̅v
𝜕𝑡

+𝜇

1 𝜕𝑂̅v
c 𝜕𝑧

=V (

𝜕𝑂̅e
𝜕𝑡

=V (

PS

𝑂̅v

𝜕𝑅e
𝜕𝑡

= 𝑘GSH 𝑂̅v + 𝑘RH 𝑂̅v (4)
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v
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𝑃
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𝑂̅e
𝑃
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𝑃
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) (2)

𝐾De

) − 𝑘GSH 𝑂̅v − 𝑘RH 𝑂̅v (3)

𝐾De

where 𝑂̅v (𝑧, 𝑡) is total concentration of free and BSA-bound oxidized 99mTc-HMPAO in the vascular region at
normalized distance z from the capillary inlet at time t, Ō𝑒 (𝑧, 𝑡) is total concentration of free and bound
oxidized 99mTc-HMPAO in the extravascular region, 𝑅𝑒 (𝑧, 𝑡) is the concentration of reduced 99mTc-HMPAO in the
extravascular region, and the model parameters are defined in Table 1.
Table 1. Model parameters
Unknown
Parameters
𝑘𝐺𝑆𝐻
𝑘𝑅𝐻
𝑃𝑆

Definition

Estimated Value

GSH-dependent reduction rate constant in extravascular region
GSH-independent reduction rate constant in extravascular
region
Capillary permeability surface area product

0.071 ± 0.030 s−1
0.031 ± 0.005 s−1
125 ± 83 mL/s

𝑃𝑒
𝐾𝐷𝑒

Ratio of protein concentration to equilibrium dissociation rate
1.12 ± 0.66
constant for oxidized HMPAO bound to protein in extravascular
region
Given Parameters
Definition
Fixed Value
𝑉𝑣
Capillary vascular volume
0.42 mL
𝑉𝑒
Extravascular tissue volume
1.0 mL
𝜇𝑐
Capillary mean transit time
2.5 s
𝑃𝑣
Ratio of BSA perfusate concentration to equilibrium dissociation 1.06
𝐷𝑣 =
rate constant for oxidized HMPAO bound to BSA in vascular
𝐾𝐷𝑣
region
BSA, bovine serum albumin; GSH, glutathione; HMPAO, hexamethylpropyleneamine oxime.
𝐷𝑒 =

Equations 2–4 are for a single capillary element. To account for the effect of capillary perfusion kinematics on
the lung uptake of 99mTc-HMPAO, a heterogeneous distribution of pulmonary capillary transit times, ℎ𝑐 (𝑡), was
used as described previously (23). ℎ𝑐 (𝑡) was represented with a gamma variate function (18) with mean transit
time 𝜇𝑐 = 2.5 s and variance σ2c = 4.0 𝑠 2 at F = 10 mL/min as determined previously (23). The ℎ𝑐 (𝑡) at F = 5 (or 15)
mL/min was obtained by rescaling ℎ𝑐 (𝑡) by dividing t by 5/10 (or 15/10) and by multiplying its amplitude by 5/10
(or 15/10) (23).
The lung input curve, 𝐶𝑎𝑟𝑡 (𝑡), was assumed to take the form of a shifted gamma variate function, which was fit
to the experimental lung inlet TAC for each data set. The arterial and venous transit time distributions were each
represented by a shifted impulse function with each shift equaling 50% of the noncapillary portion of the lung
vascular mean transit time (23). Random coupling conditions were assumed between the arteries and the
capillaries, i.e., all capillary elements are exposed to the same capillary input (3, 23).
To reduce computation time, Eqs. 2–4 for a single capillary element were solved for the capillary with the
longest transit time and then subsampled at axial points to obtain individual outflow concentration curves for
capillaries with shorter transit times (3, 23). The lung output curve, 𝐶𝑣𝑒𝑖𝑛 (𝑡), was then computed as the sum of
all capillary outflow curves, each weighted according to ℎ𝑐 (𝑡), and then shifted by the venous transit time.
Finally, the model lung time-activity curve describing the total amount of 99mTc-HMPAO in the lung as a function
of time, TAC(t), was obtained with
𝑡

TAC(𝑡) = F ∫0 [𝐶art (𝑡) − 𝐶vein (𝑡)] d𝑡 (5)

Model fitting results.
Nonlinear regression was used to fit the model solution TAC(t) to the experimental lung TACs to obtain
estimates of 𝑘𝐺𝑆𝐻 , 𝑘𝑅𝐻 , permeability surface area product (PS), and ratio of protein concentration to equilibrium
dissociation rate constant for oxidized HMPAO bound to protein in extravascular region (𝐷𝑒 ) (Table 1). To reduce
correlation between the model parameters, two lung TACs obtained from the same lung, namely pre-DEM and
post-DEM at F = 10 mL/min, were fit simultaneously. In this procedure, 𝑘𝑅𝐻 , PS, and 𝐷𝑒 were free parameters
but assumed equal for both data sets, whereas 𝑘𝐺𝑆𝐻 was free for pre-DEM data but set to zero for post-DEM
data. This approach is based on the assumption that tissue GSH is depleted after DEM administration. The
capillary volume, 𝑉𝑣 , was fixed at 0.46 mL (23) whereas the extravascular volume, 𝑉𝑒 , was set to 1.0 mL based on
lung tissue water volume estimated from lung wet weight and wet-to-dry weight ratio (6). 𝐷𝑣 = 𝑃𝑣 /𝐾𝐷𝑣 was set
to 3/1.46 since experiments were performed with 𝑃𝑣 = 3%BSA perfusate and the value obtained above for 𝐾𝐷𝑣 .
µ𝑐 was set at 2.5 s as indicated above. The model fitting was done in MATLAB with the lsqcurvefit function that
implemented the trust-region-reflective algorithm, an iterative optimization algorithm that readily incorporates
bounds on the values of the parameters. Each model fit was repeated 10 times using randomly generated initial
parameter values to avoid trapping in a local minimum solution. The largest difference between final parameter

estimates for all data fits was <0.5%, which provides reasonable confidence that a global minimum was reached
in all cases.
A representative result in Fig. 7A, obtained at F = 10 mL/min, shows good agreement between the data (points)
and the model fit (lines). Figure 8 (pre-DEM Fig. 8, left; post-DEM, Fig. 8, right) shows the corresponding
sensitivity functions that represent the normalized change in the model-fit TAC(t) for a 1% change in the value of
each free parameter (7). Note that the 𝑘𝐺𝑆𝐻 and 𝑘𝑅𝐻 functions have the identical shape and are superimposed
for the pre-DEM case, whereas the 𝑘𝐺𝑆𝐻 function for post-DEM is zero. Each of the others is different from the
others, suggesting that pre- and post-DEM lung TACs have sufficient information for estimating the model
parameters.

Fig. 7. Representative experimental lung time-activity curves (TACs; points) and simultaneous model fits
(lines). A: data acquired before (pre-) and after (post-) diethyl maleate (DEM) treatment [pump flow (F) = 10
mL/min]. B: data acquired at 3 different flows and model curves obtained with mean ± 1 SD of previously
estimated model parameters given in Table 1. ID, injected dose.
Table 2. Baseline model parameters
Model Function or Parameter
F
𝐶𝑖𝑛 (𝑡)
ℎ𝑐 (𝑡)
Arterial transit

Parameter Value
100 mL/min
µ = 0.24 s; σ2 = 0.046 𝑠 2
µ𝑐 = 0.25 s; σ2cσc2 = 0.040 𝑠 2
µ𝑎 = 0.1 s; σ2aσa2 = 0

Venous transit
µ𝑣 = 0.1 s; σ2vσv2 = 0
BSA concentration
3%
𝑘𝐺𝑆𝐻
0.07 s−1
𝑘𝑅𝐻
0.03 s−1
𝑃𝑆
125 mL/s
𝐷𝑒
1.1
BSA, bovine serum albumin; 𝐶𝑖𝑛 (𝑡), capillary input function; De, ratio of protein concentration to equilibrium
dissociation rate constant for oxidized HMPAO bound to protein in extravascular region; ℎ𝑐 (𝑡), capillary transit
time distribution; 𝑘𝐺𝑆𝐻 , glutathione (GSH)-dependent reduction rate constant; 𝑘𝑅𝐻 , GSH-independent reduction
rate constant; PS, permeability surface area product; μ, mean transit time; 𝜎 2 , variance.

Fig. 8. Model parameter sensitivity functions showing the change in the model solution given a 1% increase in
the value of the model parameter. Left: pre-diethyl maleate (DEM). Right: post-DEM. Each plot is normalized to
its maximum value. Parameters given in Table 1.
Table 1 shows the resulting estimated model parameters obtained from four different lungs. The GSHdependent rate of HMPAO reduction (𝑘𝐺𝑆𝐻 ) is ~130% larger than that for the GSH-independent rate of HMPAO
reduction (𝑘𝑅𝐻 ), consistent with lung tissue GSH being the dominant factor in HMPAO retention in lung tissue.
The estimated value of PS is large compared with the flow range studied, consistent with the oxidized form of
HMPAO being highly lipophilic with a large octanol-water partition coefficient.
The model was validated by using it in the forward mode with the estimated parameter values in Table 1 to
predict lung TACs. Figure 7B shows experimental lung TACs obtained from the same rat lung, but not one used in
the summary results of Table 1, at different pump flows together with corresponding model fits. In this case, the
model was fit to the three-flow experimental TACs simultaneously while allowing the free model parameters to
range within 1 SD of the mean values given in Table 1. Good agreement between the data and the resulting
model TAC is observed at all three flows.
The model was also used to predict the resulting lung TACs with a pump flow of 5 mL/min to compare with the
corresponding data TACs for the four rat lungs used in Table 1. The mean of the last five data points of each TAC
was compared to the steady-state value of the predicted TAC, yielding a relative error of −3.8 ± 6.0 (SD) % in the
lung uptake values.
Similarly, the model was used to predict the resulting lung TACs with 3% and 5% BSA concentration, F = 10
mL/min, and the mean estimated parameters in Table 1. The resulting model steady-state values were 2.86 and
2.00 for 3% and 5%, respectively, compared with 2.74 ± 0.27 and 1.92 ± 0.19, respectively for the data values
in Fig. 4, a difference of <5% in both cases. This result provides additional support for the model assumption of
rapidly equilibrating interactions between 99mTc-HMPAO and perfusate BSA.

Simulation results.
Simulations were performed to address questions pertinent to in vivo conditions that cannot be readily
answered experimentally. A flow of 100 mL/min, corresponding to resting cardiac output of an adult male 350-g
Sprague-Dawley rat (15), was used to determine the effect of the key model parameters on steady-state lung
uptake. The baseline simulation was performed with model parameters in Table 2, which were rescaled from
experiments performed with F = 10 mL/min or obtained from previous studies (23).
Acute lung injury is often accompanied by substantial changes in cardiac output and blood pressure in patients,
especially when accompanied with vital mechanical ventilation (20). Simulations were performed in which the
flow rate through the lung was set at 50, 100, or 150 mL/min, while the volume of each vascular component was
held constant. The steady-state values of the simulated lung TACs were determined and normalized to the
F = 100 mL/min baseline case. Results in Fig. 9 show that steady-state lung uptake is inversely related to F, in
that a 50% decrease in F resulted in a ~13% increase in lung uptake, whereas a 50% increase in F resulted in a
~8% decrease. This is expected since decreased F allows longer capillary residence times and hence increased
uptake.

Fig. 9. Lung uptake normalized to baseline case simulated with pump flow = 100 mL/min and parameters given
in Table 2. Each parameter was increased or decreased by 50%.
Previous studies have shown that in a hyperoxic model of acute lung injury vascular endothelial permeability is
increased by more than ~200% (6). Figure 9 shows that in simulations when PS was varied by ±50%, steady-state
lung uptake changed by <1%. Because the estimated value of PS is so large, these flow changes have no
measurable effect on the steady-state value of 99mTc-HMPAO uptake, which is consistent with the sensitivity
functions of Fig. 8.
Since previous studies have demonstrated that tissue GSH content plays a key role in 99mTc-HMPAO retention
(4–6, 20), simulations were performed in which 𝑘𝐺𝑆𝐻 was changed. Figure 9 shows that steady-state uptake
increases with 𝑘𝐺𝑆𝐻 , consistent with more intracellular HMPAO reduction and retention.
Data in Fig. 3, C and D, suggest an alternate pathway for 99mTc-HMPAO conversion since there is substantial
uptake even when GSH is depleted in the lung after DEM treatment. Although specific pathways have not been
clearly identified, there is evidence that mitochondrial dysfunction and/or endothelial amine metabolism
dysfunction may be contributors (4). To investigate the contribution of a GSH-independent process, simulations
were performed with 𝑘𝑅𝐻 changed by ±50%. The resulting steady-state values (Fig. 9) increased with
increasing 𝑘𝑅𝐻 , although the changes were smaller than those resulting from corresponding changes in 𝑘𝐺𝑆𝐻 .

DISCUSSION
An experimental and computational approach for mechanistic and quantitative evaluation of the
pharmacokinetics of 99mTc-HMPAO in the rat IPL was developed. The approach allows for evaluation of the
dominant factors that determine lung uptake of 99mTc-HMPAO and for separation of the contributions of
pulmonary processes from systemic processes.
The model accounts for spatial and temporal variations in the concentration of 99mTc-HMPAO on passage
through the pulmonary capillaries. The model relaxes the assumption of well-mixed compartments made in
models of 99mTc-HMPAO pharmacokinetics in other organs. The results of the model simulations demonstrate
the utility of 99mTc-HMPAO for probing tissue GSH content in intact functioning lungs and in vivo.
Sepsis, a leading cause of acute lung injury, often causes lower and variable cardiac output and blood pressure in
patients and frequently requires mechanical ventilation (22). Moreover, serum albumin can drop by half in <24
h. Data here reveal that such changes could affect lung uptake of 99mTc-HMPAO independent of a change in lung
tissue GSH content.
In the experiments presented, increasing flow from 5 to 10 mL/min, but not 10 to 15 mL/min, resulted in a
significant decrease in steady-state 99mTc-HMPAO lung uptake (Fig. 4). The pulmonary vasculature consists of
distensible blood vessels whose diameters and hence volumes are dependent on the intravascular pressure.
Previous studies using this IPL preparation showed that the microvascular pressure [(arterial pressure + venous
pressure)/2] increases from ~3 torr to ~4 torr when flow is increased from 10 to 15 mL/min (23). This increase in
intravascular pressure results in a ~6% increase in pulmonary vascular volume (14), which is offset by the 50%
increase in flow, leading to a smaller overall decrease in lung vascular mean transit time. This increase in volume
that occurs with increased flow may explain the relatively small decrease in 99mTc-HMPAO lung uptake as flow
was increased from 10 mL/min to 15 mL/min in the experiments. This effect of flow-induced changes in
microvascular pressure on lung vascular volume could be mitigated in the IPL experiments by adjusting the
venous pressure to minimize the change in microvascular pressure as pump flow is changed.
Experimental results show that before the addition of DEM 32 ± 4% of the injected 99mTc-HMPAO was taken up
and retained in the isolated lung at a flow of 10 mL/min, whereas after DEM this was decreased to 14 ± 4%. The
pre-DEM fraction is much larger than the 7.4% lung retention in vivo reported by Neirinckx et al. (20). This
difference is largely due to the large difference between the pump flow (10 mL/min) and the much higher
resting cardiac output of an adult Sprague-Dawley rat (~100 mL/min) (15). In this case 99mTc-HMPAO lung uptake
predicted by the model using the parameters in Table 1 is ~6%, providing additional validation of the model.
In the IPL studies here, and the corresponding model, there was no GSH in the perfusate. The presence of GSH in
blood plasma (~20 μM) would partially reduce 99mTc-HMPAO and hence decrease the fraction of the oxidized
form of 99mTc-HMPAO entering the lungs. At a flow of 100 mL/min, model simulations showed that decreasing
the fraction of oxidized 99mTc-HMPAO entering the lungs by 10%, 20%, or 30% decreased steady-state lung
uptake by a corresponding ~10%, 20%, and 30%.
There is strong evidence that oxidative stress plays an important role in the early stages of acute respiratory
distress syndrome (22), yet there are no good biomarkers for detection of injury before evidence of clinical
respiratory distress or infiltrates on computed tomography imaging. Unlike prior markers of lung injury that
target changes in pulmonary endothelial permeability, which is altered later in the disease progression, GSH
tissue content and the corresponding increase in lung 99mTc-HMPAO uptake occur early in the disease process
(6). In addition, our investigation of 99mTc-HMPAO is motivated by its status as a clinically approved SPECT
radiopharmaceutical in routine use.

The proposed experimental and modeling approach could be readily modified for evaluating key cellular
processes in other lung injury models by incorporating appropriate differential equations accounting for those
processes into the computational model. Also, the approach could be used directly to investigate changes in the
key model parameters that occur with lung injury and hence assess the efficacy of therapeutic treatments
thereof. The model could also be modified to quantify uptake of other biomarkers in the lung or other organs
(e.g., heart) or for analyzing data from other functional imaging modalities (e.g., MRI, PET). Moreover, the
approach can be extended to a whole body model to assess the impact of systemic circulation on the lung
uptake of HMPAO.
Model simulations performed at normal cardiac output for a rat indicated that the dominant process in steadystate uptake of 99mTc-HMPAO was GSH dependent (Fig. 9). To a lesser extent, flow played a role, but that only
became apparent when flow was changed by 50%. Changes in PS, which might be expected as a result of
vascular injury, had no effect on uptake, presumably because of the high lipophilicity of the oxidized form
of 99mTc-HMPAO. These results have important implications for in vivo preclinical studies and potential clinical
use of 99mTc-HMPAO where presumably only one time-averaged SPECT image volume would be acquired ~30
min after injection. Any observed increase in 99mTc-HMPAO in the lungs could, with fair confidence, be attributed
to an increase in a GSH-dependent process likely involved with lung injury rather than to changes in
microvascular permeability or some other process. Changes in cardiac output that may occur in patients could
be measured and accounted for in the interpretation of 99mTc-HMPAO data. Thus the modeling in these
preclinical studies is an important step toward that clinical use.
We developed an approach for studying the pharmacokinetics of a clinical SPECT biomarker, 99mTc-HMPAO, in
IPL. Experimental and modeling results indicate that tissue GSH is the dominant factor in 99mTc-HMPAO retention
in lung tissue. This approach allows investigation of questions that cannot readily be addressed in either in vivo
preclinical or clinical studies. The MATLAB code for the computational model is available for download at the
model sharing website https://www.physiome.org or upon request to the corresponding author.
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APPENDIX: DERIVATION OF GOVERNING DIFFERENTIAL EQUATIONS OF
HMPAO PBPK MODEL
HMPAO lung uptake is given by the total of oxidized and reduced HMPAO in the pulmonary arteries, pulmonary
capillary vascular and extravascular regions, and pulmonary veins. A model was developed to determine each of
these components and hence the resulting lung TAC.

Single capillary element.
Each capillary element (Fig. 6) consists of a vascular region and a surrounding extravascular region, with volumes
𝑉𝑣 and 𝑉𝑒 , respectively. The model assumes the following:
•

The lipophilic oxidized form of HMPAO can diffuse out of the vascular region into the extravascular
region driven by concentration gradient.
• Flow and hence convection are restricted to the vascular region.
• Transport within the extravascular region occurs only by diffusion.
• Instantaneous radial diffusion of both forms of HMPAO within the vascular and extravascular regions
(Ref. 3).
• Diffusion of both forms in the vascular and extravascular regions in the flow direction (x) is negligible
compared with axial convective transport (Ref. 3).
• The free (i.e., not albumin bound) oxidized form of HMPAO participates in rapidly equilibrating
interactions with perfusate albumin (BSA) in the vascular region and with other proteins and/or binding
sites in the extravascular region.
• The free oxidized form of HMPAO is converted to the reduced form via a GSH-dependent and a GSHindependent process.
• The GSH-dependent rate of HMPAO reduction in the vascular region is assumed to be zero.
• Injected HMPAO is 100% in the oxidized form.
Under these assumptions and using mass balance and laws of mass action, the temporal and spatial variations in
the concentrations of the oxidized, 𝑂(𝑡, 𝑥), and reduced, 𝑅(𝑡, 𝑥), forms of HMPAO in the blood and tissue
regions are described by the following PDEs:
𝜕𝑂
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= PS(𝑂v − 𝑂e ) + Ve (𝑘−4 𝑂e 𝑃e − 𝑘4 𝑂e 𝑃e − 𝑘3 𝑂e RH − 𝑘2 𝑂e GSH) (A3)
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where W = L/µ𝑐 is the average flow velocity within the capillary region and µ𝑐 is the capillary mean transit time
and x = 0 and x = L are the capillary inlet and outlet, respectively. 𝑂𝑣 (𝑥, 𝑡) and 𝑂𝑒 (𝑥, 𝑡) are the respective
vascular and extravascular concentrations of the oxidized form of HMPAO at distance x from the capillary inlet
and time t. 𝑃v and 𝑃𝐵 𝑂𝐵 (𝑥, 𝑡) are the respective perfusate %BSA and vascular concentration of the BSA-bound
form of oxidized HMPAO at x and t. 𝑃e and 𝑃𝑒 𝑂𝑒 (𝑥, 𝑡) are the respective concentrations of protein and proteinbound form of oxidized HMPAO within the extravascular region at x and t. GSH and RH are the concentrations of
glutathione and other reductants, respectively, within the extravascular region.
Assuming rapidly equilibrating interactions between the oxidized form of HMPAO and albumin (BSA, 𝑃v ) in the
vascular region, we obtain
𝑘−1 𝑂v 𝑃v = 𝑘1 𝑂v 𝑃v (A6)
If we let Ō𝑣 = 𝑂𝑣 + 𝑂𝑣 𝑃𝑣 = total (free + bound) concentration of the oxidized form in 𝑉𝑣 , then
𝑂̅v = 𝑂v (1 +

𝑃v
)
𝐾Dv

(A7)
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= equilibrium dissociation constant.

Similarly, assuming rapidly equilibrating interactions between oxidized HMPAO and proteins (𝑃e ) in 𝑉𝑒 , the total
(free + bound) concentration of the oxidized form of HMPAO in 𝑉𝑒 is given by
𝑃
𝑂̅e = 𝑂e (1 + 𝐾 e ) (A8)
De
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= equilibrium dissociation constant.

Substituting Eqs. A7 and A8 into Eqs. A1–A5 results in
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The boundary (x = 0) and initial (t = 0) conditions are then given by
𝑂̅v (𝑥, 0) = 𝑂̅e (𝑥, 0) = 𝑅e (𝑥, 0) = 0
𝑂̅v (0, 𝑡) = 𝐶in (𝑡) and 𝑂̅e (0, 𝑡) = 𝑅e (0, 𝑡) = 0
where 𝐶𝑖𝑛 (𝑡) is the capillary input function of the injected oxidized form of HMPAO.

Capillary bed.
The above PDEs (Eqs. A9–A11) are for a single capillary element. To account for the effect of capillary perfusion
kinematics on the lung uptake of HMPAO, an organ model was used that accounts for the distribution of
pulmonary capillary transit times, ℎ𝑐 (𝑡), and for the arterial and venous conducting vessels as previously
described (3, 23). Briefly, the lung is assumed to consist of N parallel, noninteracting capillary elements, each
with a different transit time 𝑡𝑖 , i = 1…N as shown in Fig. A1. Then ℎ𝑐 (𝑡) is the result of capillaries with different
lengths, flows, cross-sectional areas, or any combination of these. However, the per-unit capillary vascular
volume, exchange surface area, and physical and chemical properties are assumed to be the same for all
capillary elements. Then let
𝛥𝑡

𝐻𝑖 = ( 2 ) [ℎc (𝑡𝑖 −

𝛥𝑡
)+
2

ℎc (𝑡𝑖 +

𝛥𝑡
)] (A12)
2

∑𝑁
𝑖=1 𝐻𝑖 = 1 (A13)
where Hi is the flow-weighted fraction of capillaries with transit time 𝑡𝑖 and Δt is the transit time increment. All
capillaries are exposed to the same flow and capillary input function, 𝐶𝑖𝑛 (𝑡), under the assumption of random
coupling conditions between the conducting (i.e., arteries and veins) vessels and exchanging capillaries. For the

organ model, we assume no dispersion of the injected bolus in the conducting vessels so that the transit time
distributions of the arteries and the veins are represented by shifted impulse functions (23).
To determine HMPAO in the capillaries, the governing PDEs above must be solved with the above initial and
boundary conditions. A direct numerical approach is to first solve the resulting finite difference equations on
each of the N capillaries, weight the output of each capillary by its corresponding 𝐻𝑖 , and sum these weighted
curves to obtain the concentrations of the oxidized form of HMPAO in the capillary vascular and extravascular
regions at (x,t).
Because of the computational complexity of solving the system of PDEs on a distribution of capillaries, we used
an alternative strategy for obtaining the concentrations at the outlet of the capillaries. The method involves
solving the governing differential equations for a single capillary with the longest mean transit time and
subsample from that result as previously described (3, 23) and briefly presented here. Without loss of generality,
the spatial dimension can be normalized using z = x/L resulting in Ō𝑣 (𝑡, 𝑧), Ō𝑒 (𝑡, 𝑧), and 𝑅𝑇 (𝑡, 𝑧). Equation
A9 for the capillary with the longest transit time tN then becomes
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with Eqs. A10 and A11 and the initial conditions interpreted accordingly. These PDEs are then solved at each
Δt and Δz point using finite differences. Because the model produces a continuity wave that travels only in the
positive z (axial) direction, the time-concentration functions at all z locations along this maximum mean transit
time capillary can be interpreted as individual outflow concentration curves from capillaries with transit times
corresponding to the z locations. This can be seen in Fig. A2, where the concentration at the ith node of the
maximum transit time corresponds with the outflow concentration time curve for a capillary of transit time 𝑡𝑖 =
𝑖𝛥𝑡 (23).

Whole organ model.
HMPAO uptake is given by the total of oxidized and reduced HMPAO in the arteries, capillary vascular and
extravascular regions, and veins. The lung input function, 𝐶𝑎𝑟𝑡 (𝑡), was modeled as a shifted gamma variate
function (18) with mean transit time 𝜇, variance 𝜎 2 , and time shift 𝑡0 , i.e.,
0, 𝑡0 ≤ 0
𝑡 − 𝑡0
𝐶art (𝑡) = {
}
( )−1
(𝑡 − 𝑡0 ) σ2 exp (− 2
) , 𝑡0 > 0
(σ ⁄μ)
μ2

Since no dispersion occurs within the conducting arteries, the input to the capillaries, 𝐶𝑖𝑛 (𝑡), is a time-shifted
version of 𝐶𝑎𝑟𝑡 (𝑡). The capillary transit time distribution, ℎ𝑐 (𝑡), was also represented with a gamma variate
function with mean transit time (𝜇𝑐 ) and variance (σ2cσc2) equal to previously measured values reported by
Ramakrishna et al. (23). Similar to the arteries, transit through the veins is assumed to involve only a time shift
(equal to the same as the arteries). Therefore output from the lung, 𝐶𝑣𝑒𝑖𝑛 (𝑡), is a time-shifted version of the
capillary outflow curve. Finally, the model lung time-activity curve describing the total amount of 99mTc-HMPAO
in the lung as a function of time, TAC(t), is the cumulative flow-weighted sum of the lung input concentration
minus the output concentration at each time, i.e.,
𝑡

TAC(𝑡) = F ∫[𝐶art (𝑡) − 𝐶vein (𝑡)] d𝑡
0

Fig. A1.N parallel pathways corresponding to N capillaries with different mean transit times (𝑡𝑖 , where i = 1,
…, N). 𝐶𝑖𝑛 (𝑡) is the capillary input function.

Fig. A2. Solution of the model partial differential equations for the capillary with the longest transit
time. 𝐶 𝑖 corresponds to the outflow concentration for each capillary. 𝐻𝑖 is the flow-weighted fraction of
capillaries with transit time 𝑡𝑖 . F, pump flow; z, distance from the capillary inlet; 𝐶𝑖𝑛 , capillary input
function; 𝐶𝑜𝑢𝑡 , capillary output function.
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